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Introduction {#sec1}
============

The RAS/ERK pathway involved in the control of cell proliferation and apoptosis regulation is deregulated in more than 30% of human cancers ([@bib38], [@bib40]). The narrow substrate specificity and distinctive structural characteristics render MEK1/2 ideal targets for therapeutic development ([@bib8], [@bib12]). Since 2000, when the first phase I study of a MEK inhibitor (CI-1040) was carried out by Lorusso and his colleagues ([@bib21]), more than a dozen of highly specific and potent MEK1/2 inhibitors have been developed and evaluated in clinical studies ([@bib7], [@bib11]). Despite the increasing number of MEK inhibitors identified, only trametinib (GSK212), cobimetinib (GDC-0973), and binimetinib (MEK162) have gained U S Food and Drug Administration (FDA) approval for clinical use ([@bib29], [@bib34]). Other agents exhibit limited efficacy when used as a single agent and fail to demonstrate substantial clinical activity in treating tumors. One leading cause for this lack of efficacy is due to cross talks between ERK pathway and other pathways, such as PI3K-AKT pathway ([@bib4]). These have resulted in the clinical study of MEK inhibitors combined with inhibitors of PI3K, AKT, or mTOR ([@bib13], [@bib26], [@bib33]). Despite the progress obtained, these agents are only efficacious in a limited range of cancers. Therefore, there is a great need to develop new MEK inhibitors and find mechanisms that confer tumor cell resistance to MEK inhibition.

The proviral integration site for moloney murine leukemia virus (Pim-1) is a serine/threonine (Ser/Thr) kinase. The activity of Pim-1 is exclusively dependent on its protein levels, which are controlled by gene transcription and proteasome-mediated degradation ([@bib24], [@bib27]). Pim-1 displays oncogenic potential with upregulated expression in human malignancies of hematopoietic and epithelial origin ([@bib3]). Pim-1 overexpression predicts worse outcome for several human malignancies, but it also correlates with better prognosis in human prostate and pancreatic cancers ([@bib23], [@bib25]). Pim-1 is recognized as a therapeutic target, although serious side effects have stopped a clinical trial of one Pim-1 inhibitor ([@bib6], [@bib10]). Pim-1 is a critical effector mediating cross talks among different signaling pathways, especially those involving AKT and ERK ([@bib18]). It has been reported that Pim-1 plays an important role in the regulation of ERK pathway ([@bib20]). Inhibition of Pim-1 is associated with increased ERK phosphorylation, suggesting that activation of ERK-mediated survival pathways could result from Pim-1-targeted inhibition. However, whether the ERK/MAPK pathway may regulate Pim-1 activity remains unclear.

Herein, we developed a new MEK inhibitor designated as KZ-02 with AZD6244 as the starting point. KZ-02 showed ∼5-fold greater kinase inhibitory activity than AZD6244. However, KZ-02 exhibited unexpectedly high cytotoxicity of three orders of magnitude more than AZD6244. This leads to identification of Pim-1 as an additional target for KZ-02. Further studies reveal that MEK inhibition leads to enhanced Pim-1 expression, which dampens the cell-killing ability of MEK inhibitors. However, KZ-02, despite increasing Pim-1 expression due to its inhibition of MEK activation, also promotes proteasome-dependent degradation of Pim-1, ultimately inhibiting Pim-1 activation.

Results {#sec2}
=======

Development of a New MEK Inhibitor KZ-02 {#sec2.1}
----------------------------------------

The clinical importance of MEK signaling in human cancer and the limitations of existing MEK inhibitors promoted us to develop new MEK inhibitors. The starting point we used was the well-known MEK inhibitor AZD6244. AZD6244 has been reported to potently inhibit MEK1 with IC~50~ (50% inhibitory concentration) of 14 nmol/L ([@bib36]). It is currently under clinical evaluation as a single agent or in combination with other cytotoxic chemotherapy drugs or radiation therapy in various tumor types ([@bib5], [@bib30], [@bib31]). Based on the unsatisfactory potency of AZD6244, we proposed that a large substituent group on 3-nitrogen might result in a decreased antitumor activity. In addition, the de-methylation of 3-nitrogen methyl of AZD6244 could occur by *in vivo* enzyme metabolism ([@bib9]). Therefore, we replaced the 3-nitrogen methyl in the benzoheterocyclic ring of AZD6244 with S atom, generating a benzothiadiazole core. We also replaced the -Cl and -Br substituent on the aniline with -F and -I, respectively. The resulting new compound was designated as KZ-02 ([Figure 1](#fig1){ref-type="fig"}A). The step-by-step synthesis details for KZ-02 were described in [Figure S1](#mmc1){ref-type="supplementary-material"}. The corresponding analysis spectra for key intermediates and target compound were presented in [Data S1](#mmc1){ref-type="supplementary-material"}. A complex structure of MEK1/KZ-02 was built based on the MEK1/AZD6244 co-crystal structure (PDB code: [4U7Z](pdb:4U7Z){#intref0010}) ([Figure 1](#fig1){ref-type="fig"}B). The replacement of the N-methyl by a smaller group of S atom may improve the affinity between KZ-02 and MEK1. Besides, compared with AZD6244 that has one H-bond accepting nitrogen for Ser212, KZ-02 has two on the thiadiazole ring ([Figure 1](#fig1){ref-type="fig"}B), which may facilitate the binding between KZ-02 and the Ser212 of MEK1. The iodine and fluorine atom on lipophilic ring of KZ-02 may also contribute to an improved affinity by modifying the interaction of KZ-02 with the Val127 and Lys97 of MEK1. As expected, KZ-02 indeed exhibited improved potency versus AZD6244 as reflected by *in vitro* kinase inhibition assay that was carried out as a commercial service by Cerep Drug Discovery Services Co. LTD (France). The IC~50~ for KZ-02 was 1.1 nmol/L, whereas the IC~50~ of AZD6244 was determined as 5.1 nmol/L ([Figures 1](#fig1){ref-type="fig"}C and 1D). Thus, we obtained a new compound, KZ-02, that is ∼5-fold more potent than AZD6244 in MEK inhibition.Figure 1Development of a New MEK Inhibitor KZ-02(A) Chemical structure of KZ-02 and AZD6244.(B) KZ-02 structure (purple) overlapped with AZD6244 (yellow) with the co-crystal structure of MEK1/ATP/AZD6244 (PDB code: [4U7Z](pdb:4U7Z){#intref0025}) as the model. KZ-02 shows similar binding with MEK1, and key residues of MEK1 that are important for interaction with KZ-02/AZD6244 are shown.(C) In vitro kinase inhibition assay determines IC50 for AZD6244 to 5.09 nmol/L.(D) In vitro kinase inhibition assay determines IC50 for KZ-02 to be 1.07 nmol/L. Data are represented as mean ± SD.

KZ-02 Exhibits Unexpectedly Higher Cytotoxicity over AZD6244 {#sec2.2}
------------------------------------------------------------

Next, we compared the inhibitory effect of KZ-02 and AZD6244 on colorectal cancer (CRC) cell growth. Two CRC cell lines, Colo205 and HT29, were used, and these two cell lines both harbor a constitutively activated RAS/ERK pathway ([@bib17]). CRC cells were treated with increasing concentrations of compounds and cell proliferation was determined at 24, 48, and 72 h by using the MTT (methylthiazolyldiphenyl-tetrazolium bromide) method. KZ-02 significantly inhibited cell viability in a dose-dependent manner; moreover, KZ-02 exhibited higher activity than ADZ6244 in both CRC cell lines at nearly all time points ([Figures 2](#fig2){ref-type="fig"}A and 2B). The IC~50~ of KZ-02 against Colo205 and HT29 at 48 h were 0.015 and 4.1 nmol/L, respectively ([Figure 2](#fig2){ref-type="fig"}C). Compared with AZD6244, KZ-02 was three orders of magnitude more potent in inhibiting the growth of Colo205 cells (0.015 versus 15.5 nmol/L), whereas the IC~50~ of AZD6244 for inhibiting HT29 could not be determined at concentrations ranging from 0.01 to 1,000 nmol/L ([Figure 2](#fig2){ref-type="fig"}C). Considering the surprisingly increased superiority of KZ-02 to AZD6244 in MTT assay (∼1,000-fold) compared with that in MEK inhibition assay (∼5-fold), we suspected that KZ-02 might have cellular target(s) in addition to MEK.Figure 2KZ-02 Exhibits Higher Activity Than AZD6244 in Inhibiting CRC Growth(A and B) Examination of activity of KZ-02 versus AZD6244 in CRC cell growth inhibition. Colo205 (A) or HT29 (B) cells were treated with increasing concentrations of KZ-02 or AZD6244 and cell proliferation was determined at 24, 48, and 72 h by using the MTT method. Error bars are based on the standard deviations of triplicate samples.(C) IC~50~ values for KZ-02 and AZD6244 calculated from data shown in (A) and (B), and the ratio of their IC~50~s was also calculated.(D) Examination of antitumor effects of KZ-02 versus AZD6244 in xenograft models. BALB/c mice were subcutaneously injected with 1×10^7^ Colo205 cells. Mice were then randomly assigned to three groups (n = 8), vehicle, KZ-02, and AZD6244, which were orally administered once daily for 20 days. Tumor size and body weight were measured every 3 days from day 23 to day 41.(E) Body weight variations of mice used in (D).Data are represented as mean ± SD. Comparisons of two groups are performed with Student\'s t test. ∗p \< 0.05, ∗∗∗∗p \< 0.0001.

To further evaluate the antitumor effect of KZ-02 *in vivo*, we generated Colo205 colon cancer xenograft to examine the antitumor effects of KZ-02. After 20 days of oral administration, KZ-02 inhibited Colo205 xenograft growth by 56.6% at a dosage of 1 mg/kg/day; by contrast, AZD6244 showed a similar inhibition when the dosage was used as high as 10 mg/kg/day ([Figure 2](#fig2){ref-type="fig"}D). Of note, even the highest dose of drugs tested in these experiments had no apparent effect on the body weight of tumor-bearing mice ([Figure 2](#fig2){ref-type="fig"}E). These results further confirmed the superior activity of KZ-02 over AZD6244.

Pim-1 Is an Additional Target for KZ-02 {#sec2.3}
---------------------------------------

To uncover possible additional targets of KZ-02, we used the commercial service provided by the Cerep Drug Discovery Services Co. LTD (France) to perform the kinase selectivity experiment for KZ-02. The inhibitory activity values were expressed as percent of inhibitory activity of 5 mmol/L stausporin, a pan kinase inhibitor. Among the selected 77 kinases, Pim-1 ranked the second only next to MEK1, exhibiting significantly higher sensitivity to KZ-02 than the rest of the kinases ([Table S1](#mmc1){ref-type="supplementary-material"}). *In vitro* kinase inhibition assay determined the IC~50~ of KZ-02 against Pim-1 to be 1.34 μmol/L ([Figure 3](#fig3){ref-type="fig"}A). To further confirm the inhibition of KZ-02 toward Pim-1 kinase activity, we examined the effect of KZ-02 on the phosphorylation of Cdc25C, a known substrate of Pim-1 ([@bib37]). Treatment of KZ-02, in addition to blocking phosphorylation of ERK (the substrate for MEK), also led to inhibition of Cdc25C phosphorylation in both Colo205 and HT29 cells ([Figure 3](#fig3){ref-type="fig"}B). As expected, inhibition of Pim-1 activity by either Pim-1 1 (a Pim-1 inhibitor) or siRNA resulted in decreased phosphorylation of Cdc25C ([Figure 3](#fig3){ref-type="fig"}C). Together, these results demonstrate that KZ-02 is also an inhibitor for Pim-1.Figure 3KZ-02 Additionally Targets Pim-1(A) Kinase selectivity screening identified Pim-1 as an additional target for KZ-02 with IC~50~ being 1.34 μmol/L.(B) Examination of KZ-02 inhibition on Pim-1 activity. Colo205 and HT29 cells were treated with KZ-02 (10 nmol/L) or DMSO (control) for 2 h, followed by western blot analysis. Cdc25C is a known substrate of Pim-1.(C) Either Pim-1 1, a Pim-1 inhibitor, or Pim-1 siRNA treatment decreased Cdc25C phosphorylation. Cells were treated with 100 nmol/L Pim-1 1 for 2 h, or 40 nmol/L Pim-1 siRNA for 48 h, and then were lysed and subjected to western blot analysis. Data are represented as mean ± SD.

Pim-1 Inhibition Has a Synergistic Effect with MEK Inhibition {#sec2.4}
-------------------------------------------------------------

If the additional Pim-1 inhibition accounts for the surprisingly high activity of KZ-02, it is reasonable to surmise that Pim-1 inhibition may increase the cell-killing efficiency of MEK inhibition. To test this possibility, we treated Colo205 and HT29 cells with AZD6244 and Pim-1 1, individually or in combination, for 24, 48, and 72 h. The inhibitory effects of these treatments on tumor cell growth were shown in [Figures 4](#fig4){ref-type="fig"}A and 4B. Of note, Pim-1 1 itself barely inhibited proliferation of both cell lines. We then calculated the coefficient of drug interaction (CDI), which is used to evaluate drug combination effect ([@bib35]). We observed a synergistic effect in both CRC cell lines (CDI\<1), with significant synergy (CDI\<0.7) occurring for most of Colo205 cell points and a portion of HT29 cell points ([Figures 4](#fig4){ref-type="fig"}C and 4D). This result suggested that Pim-1 1 has a synergistic action with AZD6244 in suppressing tumor cell growth.Figure 4Pim-1 Inhibition Synergizes with MEK Inhibition in Inhibiting Tumor Growth(A and B) AZD6244 and Pim-1 1 show synergism in inhibiting tumor cell growth. Colo205 (A) or HT29 (B) cells were treated with AZD6244 and Pim-1 1, individually or in combination (1:1, nmol/L), for 24, 48, and 72 h. The inhibitory effects of these treatments on tumor cell growth were then measured by the MTT assay.(C) CDIs were calculated for data from (A).(D) CDIs were calculated for data from (B).(E) Evaluation of AZD6244 and Pim-1 1 combination in xenograft models. HT29 bearing xenograft mice were orally administrated with AZD6244 (20 mg/kg), Pim-1 1 (20 mg/kg), or their combination (both 20 mg/kg), and tumor volumes were examined every 3 days for 15 consecutive days.(F) CDIs were calculated for data in (E).(G) Body weights of experimental mice used in (E).Error bars are based on the standard deviations of triplicate samples for *in vitro* cell viability test and eight duplicate results for *in vivo* tumor inhibition. Data are represented as mean ± SD. Comparisons of two groups are performed with Student\'s t test. ∗p \< 0.05.

To confirm the synergism between AZD6244 and Pim-1 1, we evaluated the *in vivo* antitumor efficacy of AZD6244 and Pim-1 1 in combination versus either agent alone by using the mouse xenograft model. AZD6244, Pim-1 1 or their combination was administered orally to HT29 cell-bearing mice. We found that the combination of AZD6244 and Pim-1 1 exhibited a significant improvement of tumor suppression compared with AZD6244 and Pim-1 1 used alone ([Figure 4](#fig4){ref-type="fig"}E). The minimum relative tumor volume (tumor volume on day 15/tumor volume on day 0) for AZD6244 plus Pim-1 1 was calculated to be 1.34 with CDI values all being less than one ([Figure 4](#fig4){ref-type="fig"}F). In comparison, the relative tumor volumes for AZD6244 and Pim-1 1 when used alone were 3.13 and 5.25, respectively, and the value for the vehicle control was 5.43. Negligible body weight fluctuations indicated few adverse effects of these therapeutic treatments on laboratory animals ([Figure 4](#fig4){ref-type="fig"}G). Taken together, these results showed that AZD6244 and Pim-1 1 have a synergistic effect on killing CRC tumor cells.

MEK Inhibition Resulted in Increased Pim-1 Expression {#sec2.5}
-----------------------------------------------------

Next, we set out to investigate the mechanism behind such a synergistic action between MEK inhibition and Pim-1 inhibition. As mentioned before, inhibition of Pim-1 is previously reported to increase ERK phosphorylation ([@bib20]). We asked whether ERK/MAPK pathway might affect Pim-1 activity in return. To test this possibility, we first examined the effect of AZD6244 treatment on Pim-1 expression in Colo205 and HT29 cells. As shown in [Figure 5](#fig5){ref-type="fig"}A, AZD6244 treatment (100 nmol/L) led to a decrease of ERK phosphorylation but an increase of Pim-1 protein expression and Cdc25C phosphorylation. Consistent with this, knockdown of ERK by siRNA produced similar results ([Figure 5](#fig5){ref-type="fig"}B). We then included two additional MEK inhibitors, trametinib and MEK162, which are both approved by FDA for cancer treatment, and tested their effects on Pim-1 expression in HT29 cells. Both MEK inhibitors inhibited ERK phosphorylation and meanwhile led to an increase of Pim-1 levels as did AZD6244 ([Figure 5](#fig5){ref-type="fig"}C). Together, these results suggest that MEK inhibition increases Pim-1 expression, which could be an inherent feature for MEK inhibitors.Figure 5MEK Inhibition Increases Pim-1 Expression(A) AZD6244 increases Pim-1 levels in CRC cells. Colo205 and HT29 cells were treated with AZD6244 (100 nmol/L) for 2 h, and expression of proteins was then detected by western blot analysis with indicated antibodies.(B) Knockdown of ERK increases Pim-1 levels. CRC cells were incubated with 40 nmol/L of ERK1/2 siRNA or a scramble control siRNA for 48 h, and protein levels were detected by western blot analysis with indicated antibodies.(C) Effects of two additional MEK inhibitors, trametinib and MEK162, on Pim-1 expression. HT29 cells were treated with trametinib (100 nmol/L) or MEK162 (100 nmol/L) for 2 h, and then cells were lysed and Pim-1 levels were detected by western blot analysis.(D) The effect of MEK inhibition on Pim-1 expression in xenograft models. Four control or AZD6244-treated HT29 xenografted tumors were randomly selected to test the impact of AZD6244 on the expression of Pim-1 using western blot analysis.(E) Correlation analysis of ERK phosphorylation levels and Pim-1 protein levels in 20 CRC patient tumor specimens. Clinical colon carcinoma specimens were analyzed by immunohistochemistry (IHC). The immunoreactive score (IRS) of Pim-1 versus p-ERK for each sample was calculated. Five IRSs that have overlapped ones were labeled.(F) Representative image shows that reduced ERK phosphorylation corresponding to overexpression of Pim-1 in human colorectal tumors detected by IHC (solid red line indicated the enlarged view of the red box in each picture).(G) Representative image shows that enhanced ERK phosphorylation corresponding to the reduction of Pim-1 expression in human colorectal tumors detected by IHC (solid red line indicated the enlarged view of the red box in each picture).

To further confirm the effect of MEK inhibition on Pim-1 expression, we carried out *in vivo* analysis in HT29 cell-bearing mice. AZD6244 was administered orally at a dosage of 20 mg/kg/day for 15 days and then Pim-1 levels in control and AZD6244-treated tumor issues were analyzed by western blot analysis. As shown in [Figure 5](#fig5){ref-type="fig"}D, AZD6244 treatment led to a decrease of ERK phosphorylation, which was accompanied by an increase of Pim-1 protein levels. Finally, we examined the relationship of ERK phosphorylation levels and Pim-1 protein levels in serial slides of twenty clinical colon carcinoma specimens by immunohistochemistry (IHC). As shown in [Figure 5](#fig5){ref-type="fig"}E, ERK phosphorylation levels showed a negative correlation with Pim-1 protein levels in these clinical specimens with the negative correlation slope being −0.741. Consistently, quintessential ERK inhibition was associated with high Pim-1 positivity and vice versa as reflected by IHC assay ([Figures 5](#fig5){ref-type="fig"}F and 5G). Combined together, these results demonstrated that Pim-1 is subjected to negative regulation of ERK activation.

MEK Regulates Pim-1 via ERK/AMPK/IL-23/STAT3/Pim-1 Pathway {#sec2.6}
----------------------------------------------------------

Next, we sought to explore the possible signal transduction cascade bridging ERK and Pim-1. Since interleukin-induced STAT3 activation is the major mechanism behind Pim-1 gene transactivation ([@bib2]), we first tested the effect of AZD6244 on the expression of interleukins. We treated HT29 cells with AZD6244 for 2 h (100 nmol/L) and examined by real-time PCR the expression of several interleukins (ILs), including IL-8, IL-10, IL-16, and IL-23, which have been reported to be expressed in CRC cells ([@bib14], [@bib15], [@bib16], [@bib28], [@bib32]). We found that only IL-23 was significantly upregulated by AZD6244 ([Figure 6](#fig6){ref-type="fig"}A). IL-23 is a proinflammatory cytokine that is involved in many autoimmune diseases ([@bib28]); moreover, IL-23 has been implicated in the progression of CRCs ([@bib16]). Next, we investigated whether IL-23 may affect STAT3 phosphorylation and Pim-1 levels. We treated HT29 cells with recombinant IL-23 (10 ng/mL) for 2 h. As shown in [Figure 6](#fig6){ref-type="fig"}B, IL-23 treatment increased STAT3 phosphorylation and Pim-1 expression, whereas knockdown of IL-23 by siRNA had a reverse effect. We then asked whether IL-23 is required for AZD6244-induced increase of Pim-1 expression. For this, we treated HT29 cells with AZD6244 combined with IL-23 siRNA. As shown in [Figure 6](#fig6){ref-type="fig"}C, AZD6244 treatment increased STAT3 phosphorylation and Pim-1 expression, whereas knockdown of IL-23 abrogated these effects of AZD6244 without affecting its inhibitory effect on ERK/AMPK pathway. Of note, AMPK activation lead to a decrease of IL-23 expression ([@bib28]). Indeed, we observed that an AMPK-specific inhibitor (compound C) significantly increased the expression of IL-23, which is accompanied by an increase of STAT3 phosphorylation and Pim-1 levels; however, these effects could be reversed by knockdown of IL-23 ([Figure 6](#fig6){ref-type="fig"}D). Similarly, either MEK inhibition by AZD6244 or AMPK inhibition by compound C led to an increase of IL-23 expression ([Figures 6](#fig6){ref-type="fig"}E and 6F). Taken together, these results reveal a feedback regulation of Pim-1 by MEK through ERK/AMPK/IL-23/STAT3/Pim-1 pathway, which accounts for MEK inhibitor-induced Pim-1 upregulation and thus confers tumor cell resistance to MEK inhibition ([Figure 6](#fig6){ref-type="fig"}G).Figure 6MEK Regulates Pim-1 via ERK/AMPK/IL-23/STAT3 Cascade(A) IL-23 is specifically upregulated by AZD6244. HT29 cells were treated with AZD6244 (100 nmol/L) for 2 h, and mRNA levels of IL-8, IL-10, IL-16, and IL-23 were then detected by real-time PCR.(B) HT29 cells were treated with recombinant IL-23 (10 ng/mL) for 2 h or IL-23 siRNA (50 nmol/L) for 48 h. STAT3 phosphorylation and Pim-1 expression were then detected by western blot analysis.(C) HT29 cells were treated with AZD6244 (100 nmol/L) for 2 h with or without 48-h pretreatment with a scramble or IL-23 siRNA (50 nmol/L), and protein expression or phosphorylation levels were then detected by specific antibodies as indicated.(D) Same experiment as (C) with AZD6244 replaced by an AMPK inhibitor, compound C.(E) HT29 cells were treated either with AZD6244 (100 nmol/L) for 2 h, and then IL-23 expression was detected by real-time PCR.(F) HT29 cells were treated either with compound C (40 μmol/L) for 2 h, and then IL-23 expression was detected by real-time PCR.(G) Mechanistic model for MEK inhibition-induced Pim-1 upregulation. MEK inhibition increases IL-23 expression through ERK/AMPK signaling, which then activates STAT3, thereby promoting Pim-1 transactivation.Data are represented as mean ± SD. Comparisons of two groups are performed with Student\'s t test. ∗p \< 0.05, ∗∗∗∗p \< 0.0001.

KZ-02 Inhibits Pim-1 Activation by Promoting Its Proteasomal Degradation {#sec2.7}
------------------------------------------------------------------------

According to the findings above, as an MEK inhibitor, KZ-02 should increase Pim-1 expression. To verify this, we first assessed the effect of KZ-02 on Pim-1 protein levels in Colo205 and HT29 cells. However, unlike AZD6244, KZ-02 treatment decreased, rather than increased Pim-1 protein levels ([Figure 7](#fig7){ref-type="fig"}A). Intracellular Pim-1 protein levels were controlled by both transcriptional regulation and proteasome-mediated turn over. Considering the opposing effects of AZD6244 and KZ-02 on Pim-1 protein levels, we next compared them on their impact on Pim-1 transcriptional regulation and proteasome-mediated turn over. We first performed real-time PCR to examine possible effects of KZ-02 or AZD6244 on mRNA levels of Pim-1. MEK inhibition, either by KZ-02 or by AZD6244, is accompanied with an increase of Pim-1 mRNA levels in Colo205 cells and HT29 cells ([Figures 7](#fig7){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}A). This result is consistent with our findings above that MEK inhibition leads to an increased Pim-1 expression.Figure 7KZ-02 Inhibits Pim-1 Function by Promoting Its Proteasomal Degradation(A) KZ-02 treatment decreases Pim-1 protein levels. Colo205 and HT29 cells were treated with KZ-02 (10 nmol/L) for 2 h, and Pim-1 protein levels were then detected by western blot analysis.(B) Both KZ-02 and AZD6244 increase Pim-1 mRNA levels. Tumor cells were treated with KZ-02 (10 nmol/L) or AZD6244 (100 nmol/L) for 2 h, and Pim-1 mRNA levels were then analyzed by real-time PCR. Similar experiment in HT29 cells was shown in [Figure S2](#mmc1){ref-type="supplementary-material"}A.(C) Tumor cells were treated with either KZ-02 (10 nmol/L) or AZD6244 (100 nmol/L) for 2 h with or without addition of the proteasome inhibitor MG132 (10 μg/mL) for 30 min, and Pim-1 expression was then detected by western blot analysis. Similar experiment in HT29 cells was shown in [Figure S2](#mmc1){ref-type="supplementary-material"}B.(D) KZ-02 treatment inhibits Pim-1 and its downstream effectors, whereas AZD6244 increases their activation in Colo205 cells. Similar experiment in HT29 cells was shown in [Figure S2](#mmc1){ref-type="supplementary-material"}D.(E) Tumor cells were treated with various concentrations of KZ-02, AZD6244+Pim-1 1 (1:1), or AZD6244+Pim-1 siRNA (8 nmol/L) as indicated for 24, 48, and 72 h. MTT assay was then used to characterize the inhibition of tumor cell proliferation. Similar experiment in HT29 cells was shown in [Figure S2](#mmc1){ref-type="supplementary-material"}E.(F) IC~50~ values were calculated for data in (D) and the ratios of AZD6244+Pim-1 1 to KZ-02 IC~50~ were shown. Pim-1 knockdown efficiency was confirmed in [Figure S2](#mmc1){ref-type="supplementary-material"}C. Error bars are based on the standard deviations of triplicate samples.Data are represented as mean ± SD. Comparisons of two groups are performed with Student\'s t test. ∗∗∗p \< 0.001.

Next, we examined whether these two compounds could affect the proteasomal degradation of Pim-1. We treated tumor cells with either KZ-02 (10 nmol/L) or AZD6244 (100 nmol/L) for 2 h with or without addition of the proteasome inhibitor MG132. Pre-incubation of cells with 10 μg/mL MG132 for 30 min did not affect the increase of Pim-1 protein expression induced by AZD6244; however, MG132 abrogated the KZ-02-mediated decrease of Pim-1 protein levels in both tumor cells ([Figures 7](#fig7){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}B). These data suggested that, although both compounds upregulate Pim-1 mRNA levels, KZ-02 simultaneously promotes proteasome-dependent degradation of Pim-1.

It has been reported that Pim-1 is involved in cell-cycle regulation through phosphorylating P21^Cip1/Waf1^/P27^Kip1^ ([@bib22], [@bib39]). Moreover, Pim-1 could phosphorylate Bad to affect cell apoptosis ([@bib1]). To further confirm different effects on Pim-1 activation by KZ-02 and AZD6244, we examined their effects on activation of P21^Cip1/Waf1^/P27^Kip1^ as well as Bad in Colo205 cells or HT29 cells. As shown in [Figures 7](#fig7){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}D, although both compounds inhibited ERK phosphorylation, they exhibited opposite effects on activation of P21^Cip1/Waf1^/P27^Kip1^ and Bad. KZ-02 lead to decreased Pim-1 levels, accompanied by decreased phosphorylation of P21^Cip1/Waf1^/P27^Kip1^ and Bad; instead, AZD6244 increased phosphorylation of P21^Cip1/Waf1^/P27^Kip1^ and Bad. These results further confirmed our conclusion that KZ-02 inhibits Pim-1 activation, whereas AZD6244 increases it.

We then compared the antitumor activity of KZ-02 with that of AZD6244 and Pim-1 1 in combination via the MTT assay. The combination of AZD6244 and Pim-1 siRNA was also included for comparison. The effective Pim-1 knockdown by siRNA was confirmed ([Figure S2](#mmc1){ref-type="supplementary-material"}C). KZ-02 exhibited higher cell-killing ability than either the combination of AZD6244 plus Pim-1 1 (red versus black lines) or the combination of AZD6244 and Pim-1 siRNA (red versus blue lines) in both CRC cell lines ([Figures 7](#fig7){ref-type="fig"}E and [S2](#mmc1){ref-type="supplementary-material"}E). We then calculated IC~50~ values for KZ-02 and AZD6244 plus Pim-1 1 at 48 h of treatment, respectively. The ratio of IC~50~ value of AZD6244+Pim-1 1 versus KZ-02 was 6.8 and 72 for Colo205 and HT29 cells, respectively ([Figure 7](#fig7){ref-type="fig"}F). These results showed that KZ-02, as a dual-target inhibitor, is more effective than the combination of AZD6244 and Pim-1 1 in inhibiting CRC tumor cell growth.

Finally, we examined whether KZ-02 exclusively targets tumor cells. A potential drug candidate for cancer therapy should specifically target tumor cells with normal and benign cells spared. As shown above, KZ-02 exerted a minimal or tolerable effect on the body weight of the experimental animals ([Figure 2](#fig2){ref-type="fig"}E). To further confirm that KZ-02 specifically targets tumor cells while sparing normal or benign cells, we evaluated the potential toxicity of KZ-02, AZD6244, Pim-1 1, or AZD6244+Pim-1 1 on the immortalized normal colon cell line (CCD841CoN) over a range of dosages (0.0--10,000 nmol/L) by using the MTT assay. The corresponding tumor cell line Colo205 was used as a control (0.0--1,000 nmol/L). As shown in [Figure S2](#mmc1){ref-type="supplementary-material"}F, more than 95% of cells in the benign cells remained viable after 48 h of treatment with any of the above compounds, or their combination, even at a concentration as high as 10,000 nmol/L. By contrast, in tumor cells, a combination of AZD6244 and Pim-1 1 exhibited a concentration-dependent cell-killing activity beginning at concentration as low as 0.01 nmol/L, which was more potent compared with AZD6244 alone, but weaker than KZ-02; Pim-1 1, consistent with our results above, and had no apparent cell-killing activity when used alone ([Figure S2](#mmc1){ref-type="supplementary-material"}G). Combined together, these results showed that KZ-02 specifically inhibits tumor cell growth with better performance than the combination of AZD6244 and Pim-1 1.

Discussion {#sec3}
==========

A recent large retrospective study detected mutations in the RAS/ERK pathway for nearly half of the patients with CRC ([@bib19]), suggesting that MEK-targeted therapy could benefit a great number of patients with CRC. However, the development of acquired resistance, predominantly caused by reciprocal feedback of signal transduction pathways, will inevitably result in tumor recurrence in many cases. Understanding the feedback mechanisms underlying acquired resistance would thus facilitate the development of more effective drugs, as well as clinically relevant neoadjuvant regimens to improve the efficacy of anticancer treatment.

In this study, we initially aimed at developing a new MEK inhibitor based on the structure of the well-known MEK inhibitor AZD6244. However, the observation that KZ-02 shows remarkably more superiority to AZD6244 in the MTT assay than in the kinase assay urged us to explore the potential mechanism underlying the surprisingly high inhibitory activity of KZ-02. By using an *in vitro* kinase screening, we identified Pim-1 as an additional target for KZ-02. To our knowledge, this is the first MEK/Pim-1 dual-target inhibitor reported. Of note, KZ-02 shows less superiority over AZD6244 in xenograft mice model (∼10-fold) than in the MTT assay (∼1,000-fold). This is likely due to the inferior oral bioavailability of KZ-02 in mouse models. Further studies of pharmacokinetics and pharmacodynamics for KZ-02 would be required for evaluating and improving "drug-like" properties of KZ-02.

Pim-1 activity is dependent on its protein levels, which are controlled by transcription as well as by proteasomal degradation. Our data showed that both AZD6244 and KZ-02 increased Pim-1 mRNA levels, which could be a general mechanism underlying a compromised cell-killing ability of MEK inhibitors. Consistent with an elevation of Pim-1 activity following MEK inhibition, we find that AZD6244 induces cellular phosphorylation of Cdc25C, a substrate of Pim-1. This provides evidence that MEK pathway plays an important role in the feedback regulation of Pim-1. Further mechanistic studies revealed that inhibition of MEK could impede AMPK-mediated repression of IL-23 expression through decreasing phosphorylation of AMPK, which subsequently upregulates the transcription of Pim-1 by activating STAT3. It has been reported that Pim-1 inhibition could activate ERK ([@bib20]). Thus, our study herein reveals a reciprocal feedback loop between ERK and Pim-1. In the current study, the Pim-1 inhibitor Pim-1 1 alone exhibits no apparent inhibition against CRC tumor cells. However, when combined with AZD6244, Pim-1 1 displays a synergistic effect with AZD6244 on killing tumor cells both *in vitro* and *in vivo*. Although further clinical studies are required to address the effectiveness of this combination in treating patients with CRC, our data here clearly demonstrated that Pim-1 is an important survival factor that affects MEK-targeted treatment of CRCs, thereby identifying Pim-1 as a druggable target for enhancing the sensitivity of CRCs to MEK inhibitors. Moreover, our findings that MEK inhibition leads to AMPK suppression and STAT3 activation also suggest a possible synergistic effect between MEK inhibitors and AMPK activators or STAT3 inhibitors in CRC treatment.

KZ-02, despite increasing Pim-1 mRNA levels owing to its inhibition of MEK, causes a decrease of Pim-1 protein levels. Further studies revealed that KZ-02 could promote proteasome-dependent Pim-1 degradation. This unique activity of KZ-02 as a dual-target inhibitor endows it with superior performance to AZD6244, and even to a combination of AZD6244 and Pim-1 1. Thus far, the mechanism by which KZ-02 mediates proteasomal degradation of Pim-1 remains unknown. Pim-1 protein stability is largely dependent on its associated molecular chaperones, Hsp90 or Hsp70. Hsp90-bound Pim-1 is more stable, whereas an association with Hsp70 will lead to ubiquitination and degradation of Pim-1 ([@bib27]). Thus, one possibility is that KZ-02 may switch Pim-1 to a conformation that prefers an interaction with Hsp70. The mechanism behind how KZ-02 mediates Pim-1 degradation warrants further studies.

In conclusion, this study shows that Pim-1 activation is an important factor contributing to tumor cell desensitization to MEK inhibitors, rendering Pim-1 as a druggable target in MEK-targeted cancer therapy. Combination of Pim-1 and MEK inhibitors may serve as an effective anticancer strategy to improve CRC treatment. Moreover, a new MEK/Pim-1 dual-target inhibitor KZ-02 is developed, which exhibits a high tumor cell-killing activity by simultaneously inhibiting ERK phosphorylation and promoting proteasome-dependent Pim-1 degradation.

Limitations of the Study {#sec3.1}
------------------------

In this study, we developed a new MEK inhibitor that exhibits significantly improved antitumor activity by simultaneously targeting Pim-1. The new MEK inhibitor, designated as KZ-02, inhibits Pim-1 kinase activity as reflected by the kinase selectivity assay and the *in vitro* kinase inhibition assay. Notably, in addition to inhibiting Pim-1 kinase activity, we found that KZ-02 also decreases Pim-1 protein levels by promoting proteasomal degradation of Pim-1. Considering a mild inhibitory activity of KZ-02 against Pim-1 in the *in vitro* kinase inhibition assay but a significantly improved tumor cell-killing activity compared with AZD6244 as reflected by the MTT assay and the mouse tumor growth assay, we tend to believe that KZ-02 inhibits Pim-1 activity mainly through decreasing Pim-1 protein levels rather than inhibiting its kinase activity directly. However, so far, the cellular target and molecular mechanism behind the KZ-02-mediated Pim-1 degradation remain unclear, which absolutely warrant further investigations.
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